Actualités sur Health

Suivre
Abonner Health
Filtre
  • 14.04.2015 – 09:03

    Novo Nordisk

    Novo Nordisk Extends Programme for Children With Diabetes in Developing Countries

    Bagsværd, Denmark (ots/PRNewswire) - Today, Novo Nordisk announced a three-year extension of its Changing Diabetes(R) in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 ...

  • 13.04.2015 – 15:31

    CGI Group Inc.

    Alberta Health Extends Application Maintenance Services Contract With CGI

    Edmonton, Alberta (ots/PRNewswire) - Stock Market Symbols GIB.A (TSX) GIB (NYSE) http://www.cgi.com/newsroom CGI is pleased to announce the renewal of its application maintenance services (AMS) contract with the Ministry of Health in Alberta (Alberta Health) for three years. The original contract was signed in 2011 for three and a half years, and the high quality work ...

  • 07.04.2015 – 14:02

    Merck and Pfizer

    Global Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI® (crizotinib)

    Darmstadt, Germany And New York (ots/PRNewswire) - Not intended for UK-based media - In the second and third quarters of 2015, Merck and Pfizer will begin co-promoting XALKORI in the United States, Canada, Japan and five European Union countries (France, Germany, Italy, Spain and the United Kingdom) - In the United States and Canada, XALKORI will be co-promoted by EMD ...

  • 07.04.2015 – 13:31

    Resverlogix Corp.

    Resverlogix Receives Two Patents for RVX-208 in China

    Calgary, Alberta (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix" or the "Company") announces that it has received two China patent approvals covering RVX-208. A composition of matter patent, China No. 2007 8 0052349.8 titled, "Compounds for the Prevention and Treatment of Cardiovascular Disease" was granted until February 2027. A manufacturing patent, China No. ZL 2009 8 0106586.7 titled, "Methods of Preparing ...

  • 06.04.2015 – 14:01

    Shire Pharmaceuticals Group Plc

    Shire Comments on USPTO Petitions Related to LIALDA and GATTEX

    Lexington, Massachusetts (ots/PRNewswire) - Shire plc acknowledges the two petitions filed with the U.S. Patent and Trademark Office (USPTO) on April 2nd by Hayman Capital Management regarding LIALDA(R) (mesalamine) and GATTEX(R) (teduglutide [rDNA origin]). The patents listed in the FDA Orange Book for LIALDA and GATTEX protect the innovation and value Shire brings to patients who benefit from these important medicines. ...

  • 19.01.2015 – 08:02

    UC RUSAL

    UC RUSAL Opens a Modern Epidemiology Centre in Guinea

    Conakry, Guinea (ots/PRNewswire) - UC RUSAL , a leading global aluminium producer, announces that construction of the "Centre for epidemic and microbiological research and treatment" in the Kindia administrative region of the Republic of Guinea has completed. The Centre will support Guinea's national health system and help fight the spread of the Ebola virus. The opening ceremony which took place on 17 January was ...

  • 13.01.2015 – 16:01

    Debiopharm International SA

    Debiopharm Diagnostics Leads Investment Round in GenePOC With Emerillon Capital

    Lausanne, Switzerland (ots/PRNewswire) - GenePOC is a Canadian company which has developed a rapid, innovative, low cost MDx platform for the detection of infectious diseases Debiopharm Diagnostics [https://www.debiopharm.com/about-us/debiopharm-diagnostics-s-a.html ], part of Debiopharm Group [https://www.debiopharm.com/about-us/debiopharm-group.html ](TM), is proud ...

  • 12.01.2015 – 08:32

    Debiopharm International SA

    Debiopharm Group(TM) Regains Full Rights to Alisporivir Program

    Lausanne, Switzerland (ots/PRNewswire) - - Novartis returns Alisporivir (DEB025) to Debiopharm Group(TM) including all rights for HCV and other indications - Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that it has updated its arrangement with Novartis to regain full rights to Alisporivir (DEB025) currently completing two Phase 2 studies of interferon-free treatment in ...

  • 11.01.2015 – 17:04

    Shire plc and NPS

    PLShire to Acquire NPS Pharma as Further Step in Building a Leading Biotech

    Dublin And Bedminster, New Jersey (ots/PRNewswire) - Transaction valued at $5.2 billion Enhances growth profile Shire plc and NPS Pharmaceuticals, Inc. today announced that the companies have entered into a merger agreement pursuant to which Shire will acquire all the outstanding shares of NPS Pharma for $46.00 per share in cash, for a total consideration of ...

  • 10.01.2015 – 00:13

    Hikma Pharmaceuticals PLC

    Hikma to Launch Colchicine 0.6mg Capsules

    London (ots/PRNewswire) - Hikma Pharmaceuticals PLC ("Hikma") , the fast growing multinational pharmaceutical group, today notes that Takeda Pharmaceuticals U.S.A. Inc. ("Takeda") has been unsuccessful in appealing the decision by the United States District Court for the District of Delaware to deny Takeda's motion for a preliminary injunction in relation to the distribution of Hikma's colchicine 0.6mg capsules for the ...